Daily Stock List
Stornoway Diamond Corp. (SWY.TO)
Today we are reporting on Stornoway Diamond Corp. (SWY.TO), here at the QualityStocks Daily Newsletter.
Stornoway Diamond Corp. is a foremostCanadian diamond exploration and development enterprise. The Company’s flagship asset is the 100 percent owned Renard Diamond Project, which is on track to becoming the Province of Quebec's first diamond mine. The Renard Diamond Project is near the Otish Mountains in north-central Quebec.Stornoway also maintains an active diamond exploration program and they have advanced and grassroots programs in the most prospective regions of Canada. Stornoway Diamondlists on the Toronto Stock Exchange and on the OTC Pink Current Information under the trading symbol "SWYDF". The Company has their headquarters inLongueil, Quebec.
The Renard Diamond Project is approximately 250 km north of the Cree community of Mistissini and 350 km north of Chibougamau in the James Bay region of north-central Quebec.The Renard Diamond Project benefits from a large and expanding resource, good mining conditions, strong social acceptance, a modest environmental footprint, and the development of direct-to-mine infrastructure under the sponsorship of Quebec's "Plan Nord". The Mining Lease for Renard is valid for 20 years.
In November 2011, Stornoway Diamond released the results of a Feasibility Study at the Renard Diamond Project, followed by an Optimization Study in January of this year, which highlighted the potential of the project to become a significant producer of high value rough diamonds over a long mine life. Probable Mineral Reserves as defined under National Instrument (NI) 43-101 stand at 17.9 million carats, with a further 17.5 million carats classified as Inferred Mineral Resources, and 23.5 to 48.5 million carats classified as non-resource exploration upside.
Yesterday,Stornoway Diamondannounced the receipt of a positive Environmental Assessment Decision for the Renard Diamond Project from the Canadian Environmental Assessment Agency. The project has now received all of the major Quebec and federal government authorizations needed to begin construction.Yesterday's announcement represents the culmination of all public consultations and regulatory assessments arising from the project's Environmental and Social Impact Assessment (ESIA). Operating permits can now be pursuedfor site specific activities under the authority of the overall global authorizations.
Stornoway Diamond Corp. (SWY.TO), closed Wednesday’s trading session at $0.53, up 1.92%, on 510,524 volume. The stock's 52-week low/high is $0.45/$0.99.
Novation Holdings, Inc. (NOHO)
PennyStocks24, Bird Gang Stocks, and PennyStockLocks.com reported recently on Novation Holdings, Inc. (NOHO), OTCBB Journal, First Penny Picks did earlier, and we are highlighting the Company as well, here at the QualityStocks Daily Newsletter.
Novation Holdings, Inc. is an operating holding company that lists on the OTC Markets’ OTCQB. The Company has subsidiaries in the ISP business (Burgoyne Internet Services, Inc.), in language immersion for children (Casita de los Ninos, LLC, a California limited liability company doing business as Immersion House) and in administrative and financial management (Novation Consulting Services, Inc.). Novation Holdings has their headquarters in Boca Raton, Florida.
The Company also holds a controlling interest in Crown City Pictures, Inc. Crown City Pictures is the parent company of StarPoint USA, Inc.StarPoint USAis a U.S. based vehicle distribution company.Novation Holdings also holds a controlling interest in Solar Energy Initiatives, Inc., which operates in the solar energy space and has a wholly-owned restaurant operating subsidiary.
Novation Consulting Services is the administrative subsidiary of Novation Holdings. They additionally provide in-house financial services, including accounting, bookkeeping, and budget, and financial statement preparation, preparation of SEC periodic filings, EDGAR filing conversion, XBLR filings, banking support and likeservices. They also provide "in-house" corporate counsel services, compensation management support, HR, IT support and other such services to Novationand to their controlled public affiliates and to other unrelated public companies.
Yesterday, Novation Holdings announced that they determined that the Company is no longer a development stage company. Novation will now file their periodic SEC reports as a regular, full reporting public company. According to Mr. Michael Gelmon, Chairman and Chief Executive Officer of Novation: "As a result of our acquisitions of several operating subsidiaries at the beginning of this calendar year, and the integration of their operations, we expect to report a slight net profit for the quarter ended May 31, 2013 and hope to also reflect a net profit for the full year ending August 31, 2013. That, coupled with our more recent acquisitions of controlling interests in two other public companies, puts us on track for the next fiscal year, and a positive return for our shareholders."
Novation Holdings, Inc. (NOHO), closed Wednesday’s trading session at $0.0017, up 70.00%, on 132,336,408 volume with 240 trades. The average volume for the last 60 days is 13,839,192 and the stock's 52-week low/high is $0.0005/$0.1424.
Western Sierra Mining Corp. (WSRA)
Stocks Gone Wild reported earlier on Western Sierra Mining Corp. (WSRA), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Founded in 1907, Western Sierra Mining Corp. engages in non-ferrous mining in the United States and Mexico. Based inLake Havasu City, Arizona, the Company is principally a project development enterprisethat can take a potential target mining property from exploration to production either for their account or as a Joint Venture (JV) partner or operations contractor for others.An exploration stage company,Western Sierra Mining lists on the OTC Pink Current Information.
In addition, the Companyprovides an assortment of services to the mining industry. This includes project management, project certifications and evaluations, mine engineering, as well as environmental permitting. Western Sierra Mining,as of November 17, 2011, operates as a subsidiary of Gear International, Inc.
Western Sierraearlier acquired mineral properties in the Bradshaw Mountains of Arizona. These include The Sun Gold Group, The Big Chief Group, The Oro Cache Mine, The Eagle Mine and The Treasure Gulch Mine. Total reported gold reserves for this group are approximately 500,000 oz of gold and 900,000 oz of silver (100,000 oz Au proven, 400,000 oz Au probable/indicated and 550,000 oz Ag proven and 350,000 oz Ag probable/indicated).
The Companyholds interests in the Gold Basin mine consisting offour claims located on approximately 332 acres in central Arizona; the Gold River mines situated in the Bradshaw Mountains; and the Mud Springs property located in Crescent Valley.
Mr. Michael Chaffee is the President and Chief Executive Officer of Western Sierra Mining. Mr. Chaffee has more than 30 years of mining experience and an extensive work history in the Senior Management of public companies. Hewas previously the President, CEO, and Chairman of Applied Biomedical Sciences (ABS); a public company of which he was a founding director. Before establishing ABS, he held senior positions as Executive Vice President and COO of U.S. Pump and Turbine Company, Inc., Vice President, Western Regional International as well as being a Senior Vice President in two local Investment Banking firms.
Western Sierra Mining Corp. (WSRA), closed Wednesday at $0.0072, up 213.04%, on 8,084,958 volume with 284 trades. The average volume for the last 60 days is 45,240 and the stock's 52-week low/high is $0.0017/$0.0095.
MediSwipe, Inc. (MWIP)
StockHideout and OTCJournal reported last week on MediSwipe, Inc. (MWIP), Stock Analyzer, PennyStocks24, PennyStockCrowd did earlier, and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
MediSwipe, Inc. is a data management solutions company for the medicinal marijuana and health care industry. The Company provides inventive patient solutions for electronically processing transactions within the healthcare industry. Theyoffer a comprehensive line of merchant services for a medical business. This includes Visa, MasterCard & merchant accounts, debit & credit card transaction processing, gift/loyalty card programs and POS terminals.The Company provides online and wireless merchant payment solutions globally.MediSwipe’s shares trade on the OTCQB.
The Company provides terminal-based service packages and integrated Web Portal add-ons for physicians, clinics, hospitals and medical dispensaries. Thisincludes digital patient records, Electronic Referrals, Check Guarantee and Accounts Receivable Financing.In addition, MediSwipe has reseller programs for agents and referral partners, internet affiliates and value-added resellers.MediSwipe’s alliances provide an electronic payment processing suite of services that enable merchants to accept diverse credit and debit cards, as well as ATM cards and ACH check drafts for payment to a retail, service, mail-order, or Internet merchant.
Today, MediSwipeannounced that they agreed to a new two year licensing agreement with Chill Drinks, LLC for the hemp based energy drink "Chillo" and C+ Swiss Hemp Tea. The terms of the agreement will allow MediSwipe to remain the exclusive provider of the popular drinks to all medical dispensaries, pharmacies, approved retail locations, Amazon and e-commerce sites. This amended two year agreement also includes Chillo merchandising rights (T-shirts, hats, glasses, and more) as additional retail revenue streams for MediSwipe.
Chillo has the chill of hemp seed extract and a blend of caffeine, vitamins B6 and B12.Moreover, Chill Drinks offers their brand of hemp-based tea C+ Swiss. C+Swiss is popularly known as the original hemp based ice tea approved for sale in the U.S. The hemp based drink comes in eco-friendly, recyclable packaging and it contains all natural ingredients including non-gmo beet sugar, concentrated lemon juice, hemp seed extract, black tea extract, and natural flavoring consisting of fruit and plant extracts.
MediSwipe, Inc. (MWIP), closed Wednesday’s trading at $0.0389, up 2.64%, on 2,674,820 volume with 119 trades. The average volume for the last 60 days is 2,246,395 and the stock's 52-week low/high is $0.001/$0.1274.
Hemp, Inc. (HEMP)
FeedBlitz, Money Morning, TopStockAnalysts, OTCJournal, The Green Baron, Penny Stock Rumble, and MicrocapAlliance reported earlier on Hemp, Inc. (HEMP), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.
Hemp, Inc. engagesin the research and development of all things made of industrial hemp. This includes from clothing to nutraceuticals.Hemp is a variety of cannabis that is grown for the fiber and seeds. Hemp does not contain psychoactive compounds and is legal in the United States and most of the world. Incorporated in Colorado in 2008, part of the Company’svision is foreseeing the potential global benefits that may be derived from the array of uses for industrial hemp.Hemp lists on the OTC Pink Current Information and the Company is based in Las Vegas, Nevada.
Herbagenix™ supplements are a hemp based nutrition product formulated by Hemp.Herbagenix™ products ingredients are all natural and organic, without the chemicals common in western agriculture. No ingredients are genetically modified. They are grown from plants with lineage going back thousands of years.
Hemphas partnered with Hemp.com, which is the premier domain name in the industry. Hemp.com has a long history as a URL and a solid foundation.The intention of Hemp.com is to become the “go to” site for all things hemp. This will provide the community a digital stage to share information and products.The Hemp.com Marketplace (a centralized Hemp Store) will allow artisans to stand alongside industry icons to showcase their wares.
Last week,Hemp announced their first $200,000 sale after signing an exclusive agreement with CleanPath Resources Corp. (CLNP). This agreement is for CleanPath to distribute Hemp’snutraceutical, "Focus™". The design of Focus™is to support "Clearer Thinking" and "Improve Memory". Focus™ is a blend of potent herbs and blue-green algae, with an added compliment of B Vitamins, Coenzyme Q-10, DHEA, Acetyl L-carnatine, Citicoline, and Phosphatidylserine.
According to Hemp executives, the Company has already collected more than $200,000 of income in "Focus™" sales from CleanPath.CleanPath signed an exclusive marketing agreement with the Herbagenix™ division of Hemp to distribute the product throughout the United States, Canada, and Mexico.
Hemp, Inc. (HEMP), closed Wednesday’s session at $0.02, down 4.76%, on 4,991,438 volume with 114 trades. The average volume for the last 60 days is 4,010,033 and the stock's 52-week low/high is $0.01/$0.15.
Discovery Minerals Ltd. (DSCR)
PennyStocks24, Pennybuster, and Lions of Wall Street reported this month on Discovery Minerals Ltd. (DSCR), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.
Incorporated in 2005, Discovery Minerals Ltd.is ametals exploration and development company whose shares trade on the OTC Pink Current Information. Their focus is onprojects in the Western U.S. and California more specifically. A production stage company, Discovery Mineralsestablished to acquire and develop natural resource properties. The Company’s activities include gold, precious metals and minerals. This includes rare earth minerals production and sales.
Discovery Minerals has their corporate headquarters in Reno, Nevada.The Company previously went by the name Dhanoa Minerals, Ltd. They changed their name to Discovery Minerals, Ltd. in August of 2012.The Company has initiated a new program to evaluate undervalued assets, including clean tech and alternative energy investments, for potential addition to their portfolio.
Discovery Minerals is pursuing several environmentally friendly projectsthat incorporate numerousexclusive licences.These licences are in integrated, ecologically sound areas. These include low cost, low carbon footprint, innovative water desalination technology, low energy consumption LED lighting, and low cost eco-housing that includes advanced self- contained solar lighting and heating.
Recently,Discovery Minerals’Chief Executive Officer, Mr. Russell Smith, announced that the Company is implementing a Three-Step Plan to get the Company on track to success. Discovery already took steps to enhance their public disclosure on OTC Markets by remaining current in their reporting obligations. Corporately, they amended their Articles of Incorporation and Corporate Bylaws to create a series of Anti-Dilutive, Convertible Preferred Shares to protect their majority stakeholders. These securities will soon become available to the common shareholders. The Company’s mandate, moving ahead, is to begin reorganizing the debt on the balance sheet, so the company is debt-free.
Next, their intention is to register their securities to become an OTCBB company. The third part of the plan is to enhance the Net Stock Holders' Equity in the Company through acquiring or joint-venturing with profitable mining operations, and/or assets, using the Company’s Convertible Preferred Stock as currency.
Last week, Discovery Minerals announced the finalization of the merger and acquisition of Deer Park Development Corp., a Nevada real estate company, as a wholly-owned subsidiary. The acquisition is an all-stock transaction, with a share exchange agreement for convertible preferred stock, the final terms of the transaction being disclosed in the Company's Disclosure documents, on or before July 31st, 2013.
Discovery Minerals Ltd. (DSCR), closed at $0.0015, up 50.00%, on 90,943,624 volume with 193 trades. The average volume for the last 60 days is 6,109,372 and the stock's 52-week low/high is $0.0009/$0.05.
Panoro Minerals Ltd. (PML.V)
Today we are highlighting Panoro Minerals Ltd. (PML.V), here at the QualityStocks Daily Newsletter.
Panoro Minerals Ltd. is a mineral exploration company focusing on exploring and advancing their significant portfolio of large- potential copper and copper/gold deposits in Peru. At present, the Company owns 13 copper and gold properties in the prolific Andahuaylas-Yauri copper-gold province in Southern Peru, and one polymetallic project in the Northwest. Panoro Minerals’ shares trade on the TSX Venture Exchange. The Company has their corporate headquarters in Vancouver, British Columbia.
Panoro’s flagship properties are the advanced stage Cotabambas and Antilla projects. The Cotabambas project contains an NI 43-101 compliant inferred resource of 404.1 million tonnes with an average copper grade of 0.42%, an average gold grade of 0.23 g/t and an average silver grade of 2.84 g/t, applying a cut-off grade of 0.2% copper equivalent. The Company completed a 24,400m step-out and infill drill program in September 2012.
The Antilla project has an NI 43-101 resource of 154 million tonnes at 0.47% copper and 0.009% molybdenum. This includes a high grade zone of 70 million tonnes at 0.56% copper and 0.011% molybdenum at a cut-off grade of 0.25% copper.
This week, Panoro reported additional assay results from their 100 percent owned Cotabambas porphyry copper-gold-silver project located in southern Peru. Drillhole CB-139 intersected 128.9m of primary copper mineralization grading 1.29% Cu, 0.96g/t Au and 9.4g/t Ag. This includes 59.7m averaging 1.64% Cu, 1.30g/t Au and 10.3 g/t Ag. This is underlain by a second interval of 198.6m of primary copper mineralization grading 0.48% Cu, 0.24g/t Au and 4.7g/t Ag, including 48.0m grading 0.82%Cu, 0.41 g/t Au and 8.3 g/t Ag.
Drillhole CB-138 intersected 55.7m of primary copper mineralization grading 0.93% Cu, 0.74 g/t Au, 6.5g/t Ag, underlain by another interval of 67.4m averaging 0.61% Cu, 0.33g/t Au, 4.1g/t Ag. This includes 46.0m grading 0.79% Cu, 0.46g/t Au and 4.9g/t Ag.
Drillhole CB-120 intersected 46.8m of copper oxide mineralization grading 0.89% Cu, 0.07g/t Au and 0.9 g/t Ag in a broader interval of 155.3m averaging 0.60% Cu, 0.06g/t Au and 1.0 g/t Ag.
Panoro Minerals Ltd. (PML.V), closed Wednesday’s trading session at $0.33, up 17.86%, on 283,953 volume. The stock's 52-week low/high is $0.23/$0.86.
Eco-Tek Group, Inc. (ETEK)
TooNiceStocks, Equity Observer, Pumps and Dumps, ShazamStocks, Penny Stock Rumble, Wealthpire Inc., Perfect Penny Stocks, PennyAuthority.com, Eastwind Research, and StockBomb.com reported on Eco-Tek Group, Inc. (ETEK), and we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Eco-Tek Group, Inc.specializes in the development and marketing of innovative and cost effective green lubrication and filtration products. Theirproducts have a broad spectrum of applications in the transportation, marine, and industrial sectors.The Company's products sell to the end user/consumer in retail outlets, and direct to businesses for fleet applications. Eco-Tek Group lists on the OTCQB. The Company is based inWoodbridge, Ontario.
Eco-Tek has sold their products primarily in the Province of Ontario market for the past three years.However, they are now set to expand their operations by selling throughout North America and globally.The Company’s mission is to provide a cleaner environment; reduction of fuel consumption; reduction of oil consumption; longer lasting engines and equipment; reduced maintenance, as well as increased resale value.
This week, the Company announced thattheir Eco-Tek 4 in 1 Fuel Treatment for Gasoline was certified by the United States Environmental Protection Agency. Eco-Tek managementbelieves that this EPA Certification provides a competitive advantage, and that it should benefit Eco-Tek to gain entry into Big Box retailers in North America.
Furthermore, this week, Eco-Tek announced that their "Eco-Tek Group Inc." oil filtration systems and lubricant products will be exclusively marketed in Peru via an agreement with Prieto Topo Grafia – Peru. The distributor placed an initial order for $50,000 (approximately 35 systems) that is undergoing assembly for immediate shipment. Additionally, the agreement requires Prieto Topo Grafia to purchase a minimum of Cdn. $50,000.00 of the bypass system products during each 12 month period following the signing of the five year agreement.
Today,Eco-Tek Group announced the Eco-Tek ByPass 24 Program. This program combines a blend of Eco-Tek lubricant products with the Company’s ByPass Filter System. Consequently, this creates an oil care program unique to the marketplace. Customers who join the program pay a low monthly fee for the ByPass Filter System. They subsequently receive the system, installation, and all filter supplies, oil and lab reports for a two year period.
Eco-Tek Group, Inc. (ETEK), closed Wednesday’s trading session at $0.27, down 22.86%, on 2,095,624 volume with 448 trades. The average volume for the last 60 days is 76,288 and the stock's 52-week low/high is $0.15/$0.95.
Rafarma Pharmaceuticals, Inc. (RAFA)
The QualityStocks Daily Newsletter would like to spotlight Rafarma Pharmaceuticals, Inc. (RAFA). Today, Rafarma Pharmaceuticals, Inc. closed trading at $0.65, up 35.42%, on 35,075 volume with 26 trades. The stock’s average daily volume over the past 60 days is 54,527, and its 52-week low/high is $0.041/$0.98.
Rafarma Pharmaceuticals, Inc. operating subsidiary, ZAO Rafarma, which handles day-to-day production activities, as well as operational and business expansion, brought in a new Board of Directors today, consisting of a highly-qualified team of pharmaceutical industry and business professionals. These Board additions will facilitate maximum use of the new 270k square-foot, state-of-the-art manufacturing and distribution facility in Russia, which produces generic antibiotics and specialty pharmaceuticals in addition to its own line of proprietary products that are approved by the Ministry of Health of Russian Federation.
Rafarma Pharmaceuticals, Inc. (RAFA) is a multiproduct pharmaceutical company specializing in the production of generic antibiotics and specialty pharmaceuticals, including its own proprietary products approved by the ministry of health. Rafarma stands as one of the most ambitious projects in recent medical history, having constructed the most technologically advanced pharmaceutical plant in Russia.
Based in Terbuny, Lipetsk region, Russia, Rafarma possesses a unique niche in the burgeoning pharmaceutical market and is poised to become a major player in the international drug industry. The company was established under the auspices of the Foundation to Support Health Care and has been approved by the Ministry of Health.
Rafarma recently received the general license for pharmaceutical products and began manufacturing three new products: Sodium Para-Aminosalicilate, Ibuprofen, and Betagistin. Receiving the general license was one of the final steps the company needed to open its new plant in Terbuniv, and Rafarma has been named one of only four national strategic pharmaceutical suppliers to the Russian Federation.
Advances in health care science, medicine, and technology have increased the general life expectancy of Eastern European citizens steadily over the past decade. Elderly citizens, which comprise the largest portion of the pharmaceuticals market, have bolstered demand for pharmaceuticals nationwide. Rafarma is well positioned to capitalize on the expanding industry with its strong relationships and state-of-the-art production facility. Disclaimer
Rafarma Pharmaceuticals, Inc. Company Blog
Rafarma Pharmaceuticals, Inc. News:
Rafarma Pharmaceuticals Operational Subsidiary Introduces New Board of Directors
Rafarma Pharmaceuticals Enters Into New Exclusive Production Contract With JSC F-Synthesis to Produce Anti-Cancer Drug Imatinib
Rafarma Pharmaceuticals, Inc. (RAFA) Enters Into New Production Contract for Para-Aminosalicylic Acid
GRILLiT, Inc. (GRLT)
The QualityStocks Daily Newsletter would like to spotlight GRILLiT, Inc. (GRLT). Today, GRILLiT, Inc. closed trading at $0.28, up 3.70%, on 45,330 volume with 27 trades. The stock’s average daily volume over the past 60 days is 6,853, and its 52-week low/high is $0.11/$1.50.
GRILLiT, Inc. reported today that they have successfully executed a letter of intent to acquire an existing eatery to retrofit for their third restaurant location in South Florida, right in the middle of a prime, high-traffic area adjacent to the University of Miami. GRILLiT CEO, Raymond Dias, stated, "We are extremely pleased to have the opportunity for this store location. It is a perfect fit for us, both in terms of the existing store being a relatively simple retrofit, as well as being in an ideal area that gives us exposure to the large student population."
GRILLiT, Inc. (GRLT) was founded on the concept of delivering a fast-casual dining experience with fresh, nutritious home-style cooking. Leveraging more than four decades of experience in the food industry, the founders of GRILLiT established this unique business model to satisfy the ever-increasing demand for delicious and healthy food while providing the perfect ambiance for guest to relax and enjoy great cuisine.
The company sources its ingredients from local and domestic farmers to ensure crisp, fresh produce and grain-fed Angus beef. The cooking techniques and low-sodium recipes employed result in uniquely healthy and delectable meal choices. Using the best possible ingredients, GRILLiT chefs have created an inspiring flavor profile using fresh herbs spices and all-natural marinades.
The management team executing GRILLiT’s business strategy has been carefully assembled to achieve rapid growth and profitability. One of the most recent additions, Rob Elliott, brings more than 25 years of experience in restaurant franchise system development, marketing, branding, and operations. Previously serving as Vice President of Marketing for Little Caesars Pizza, he was instrumental in expanding the number of store locations from 150 to 5,000.
GRILLiT is focused on expanding throughout the southeastern United States and offers nationwide franchising opportunities. Current locations operate in high-traffic shopping plazas and offer American, Asian Fusion, and Latin American food styles. The company’s growth strategy is based on a five-year plan to roll out a total of 79 stores in nine States: Florida, Kentucky, Ohio, New Jersey, New Hampshire, North Carolina, Tennessee, Georgia, and Pennsylvania. Disclaimer
GRILLiT, Inc. Company Blog
GRILLiT, Inc. News:
GRILLIT® Enters LOI to Acquire Third Restaurant Location Near University of Miami Campus
GRILLiT® Brings Top Franchise Branding/PR Firm Aboard
GRILLiT®, Inc. Announces Common Stock Dividend to its Shareholders
Advaxis, Inc. (ADXSD)
The QualityStocks Daily Newsletter would like to spotlight Advaxis, Inc. (ADXSD). Today, Advaxis, Inc. closed trading at $4.38, off by 15.77%, on 18,003 volume with 57 trades. The stock’s average daily volume over the past 60 days is 6,109, and its 52-week low/high is $3.4375/$19.375.
Advaxis Inc. announced updated preliminary data today from a dose escalation Phase 1 study evaluating the safety and efficacy of their ADXS-cHER2 indication for the treatment of dogs with osteosarcoma that overexpress human epidural growth factor receptor-2 (or HER2). With extremely encouraging preliminary results and very mild side effects where present, the company now has a clear route to commercial success in the veterinary medical market and they have gone into talks already with several key veterinary health companies.
Advaxis, Inc. (ADXSD) is a clinical-stage biotechnology company developing the next-generation of immunotherapies for cancer and infectious diseases. The company’s immunotherapies are based on a novel platform technology that uses live, bio-engineered bacteria to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to fight off cancer and disease.
The company has more than fifteen distinct constructs in various stages of development, all of which are involved in strategic collaborations with recognized centers of excellence such as the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others.
Advaxis’ lead construct, ADXS-HPV, is currently in Phase 2 clinical development for recurrent/refractory and advanced cervical cancer, CIN 2/3, and HPV caused head and neck cancers. This important construct was recognized as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards by the vaccine industry and the journal Expert Reviews of Vaccines.
The estimated global market for immunotherapies is projected to exceed $37.2B by 2012, with cancer vaccines forecast to grow into an $8B market. Protected by 77 issued and pending patents, Advaxis is extremely well positioned to capitalize on the burgeoning opportunities in the healthcare sector as it advances the development of next-generation treatments for today’s most challenging diseases. Disclaimer
Advaxis, Inc. Company Blog
Advaxis, Inc. News:
Advaxis Announces ADXS-cHER2 Demonstrates Significant Survival Advantage in Ongoing Canine Osteosarcoma Study
Advaxis Announces Appointment of New Member to Its Board of Directors
Advaxis Announces 1-for-125 Reverse Stock Split and Decrease in Authorized Shares of Common Stock
VentriPoint Diagnostics Ltd. (VPTDF)
The QualityStocks Daily Newsletter would like to spotlight VentriPoint Diagnostics Ltd. (VPTDF). Today, VentriPoint Diagnostics Ltd. closed trading at $0.0985, up 36.43%, on 35,000 volume with 3 trades. The stock’s average daily volume over the past 60 days is 19,171, and its 52-week low/high is $0.055/$0.1595.
VentriPoint Diagnostics Ltd. (VPTDF) leverages knowledge-based techniques to make heart analysis more convenient and less expensive. Having already installed multiple VMS™ analysis systems for heart testing in leading cardiac centers in Europe, Canada and the United States, the company is currently focused on expanding the applications of its technology beyond congenital heart disease in adults and children.
VMS™ is the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. The company designed its analysis system to be used for all major heart diseases, including pulmonary hypertension, cardiovascular disease, and heart failure. Canada and Europe (CE Mark) have granted approval for the sale of the VMS™ diagnostic tool, and VentriPoint is pursuing the US-FDA approval through the 510(k) process.
The company’s VMS™ analysis systems eliminate all the disadvantages of an MRI scan, including a long wait list, the one-hour scan time, the claustrophobic environment, the requirement of a general anesthetic for children, the lengthy heart analysis process, and the need for a second trip to the hospital. Offering better efficiency and cost savings, VMS™ offers the healthcare industry a superior method of heart visualization.
The management team executing VentriPoint’s business strategy retains extensive experience in both healthcare technology and business development. Many expansion opportunities exist for the company’s technology with a total market potential exceeding $1 billion. As a leader in the clinical diagnostics market, the company is well positioned to meet the well-defined clinical need for efficient, accurate, and inexpensive heart analysis. Disclaimer
VentriPoint Diagnostics Ltd. Company Blog
VentriPoint Diagnostics Ltd. News:
VentriPoint Announces Closing of Private Placement and Corporate Update
Ventripoint Announces New Vice-President of Sales and Marketing
VentriPoint Announces Closing of Private Placement and Proposed Issuance of Shares for Debt
Rafarma Pharmaceuticals, producer of generic antibiotics and specialty pharmaceuticals in addition to its own line of proprietary products, today issued a press release announcing its operational subsidiary’s Board of Directors. Comprised of industry veterans, the well-qualified team is presented below:
Nadezhda Brusnitsina, Chairman of the Board – Former director of the MBA program for the Russian Academy of National Economy and State Service, under the President of the Russian Federation, where she was also a Professor in the Department of Project Management. Ms. Brusnitsina has a PhD in Economics and over 13 years’ experience in management.
Irina Shashkova, First Deputy to Director-General – With more than 30 years’ experience in various pharmaceutical enterprises, Ms. Shashkova provides a broad range of skills in the industry. She was awarded a certificate of excellence by the Ministry of Health of Russian Federation for her work in advancing pharmaceutical initiatives in Russia.
Andrey Sinitsin, M.D. – Dr. Sinitsin is a medical professional with over 10 years’ experience in marketing and sales of pharmaceutical products. Mr. Sinitsin has been a key contributor in growing Rafarma, particularly in the procurement of production contracts for the company.
Mikhail Nazarychev – Mr. Nazarychev’s experience and skill set are in investment and commercial banking. Mr. Nazarychev obtained his educational degrees at the Russian Federation Finance Academy where he majored in banking and finance. Mr. Nazarychev has played a key role in the financing of the company’s growth and expansion.
Tatiana Leontieva, J.D. – A graduate of Moscow University in Social law, Ms. Leontieva is a seasoned corporate professional who also has held important government positions for the Russian Federation. Ms. Leontieva was part of the team that initiated and founded ZAO Rafarma. She also holds board positions, including a chairmanship, with industry-related companies.
Hartmut Gerlof – Vice President of Textima, Germany. Mr. Gerlof brings to Rafarma a lengthy history of corporate management of large companies within the industry. Mr. Gerlof’s experience allows him to facilitate relations with the German Science and Manufacturing communities for the expansion of Rafarma’s revenue opportunities in Germany.
Professor Dr. Hartwig Steckel – Dr. Steckel is a licensed pharmacist as well as the Director of the Department of Pharmaceutics and Biopharmaceutics (Institute of Pharmacy) at Christian Albrecht University in Kiel, Germany. Dr. Steckel is also a member of the International Association for Pharmaceutical Technology (APV), the American Association for Pharmaceutical Scientists (AAPS) and the German Pharmaceutical Society (DPhG).
CEO Dave Anderson commented, “We welcome these new members and look forward to working closely with such a diverse and experienced board.”
For more information on Rafarma, visit www.Rafarma.com
Today before the opening bell, GRILLiT announced the execution of a letter of intent (“LOI”) to acquire an existing restaurant. After a low-cost retrofit, the location would serve as the company’s third location in South Florida.
Located in a well-trafficked area next to the University of Miami, the restaurant is expected to be in GRILLiT’s possession no later than August 27, 2013. GRILLiT has already paid the initial deposit into escrow as required by the terms of the LOI.
GRILLiT CEO, Raymond Dias, stated, “We are extremely pleased to have the opportunity for this store location. It is a perfect fit for us, both in terms of the existing store being a relatively simple retrofit, as well as being in an ideal area that gives us exposure to the large student population.”
GRILLiT’s healthy, fast-casual restaurants offer American, Asian Fusion, and Latin American food styles. The company’s restaurants are known for their great atmosphere, casual dining, and freshly prepared lunch and dinner options. The company is focused on expansion throughout Florida and the southeastern United States and nationwide franchising opportunities.
For more information, visit www.grillitinc.com
Advaxis, a clinical-stage biotech company developing next-generation immunotherapies for cancer and infectious diseases, today issued updated preliminary data from a dose escalation phase 1 study evaluating the safety and efficacy of ADXS-cHER2 in the treatment of dogs with osteosarcoma that overexpress human epidural growth factor receptor-2, or HER2.
Osteosarcoma, the most common primary bone tumor in dogs, is an aggressive tumor accounting for roughly 85 percent of tumors on the canine skeleton. Dogs undergoing standard of care (SOC) treatment, which includes amputation of the affected limb followed by chemotherapy, have a median survival rate of only one year.
ADXS updated preliminary data from the first two of three dose groups (six dogs/three dogs per dose group), reporting a significant survival advantage for dogs that received SOC plus ADXS-cHER2 compared to 11 dogs whose owners elected not to participate in the trial but who were followed for survival. At this point in the study, eight of nine dogs treated with ADXS-cHER2 are alive (average survival undefined), compared with five of 11 dogs in the control group (average survival 265 days).
ADXS-cHER2 continues to be well-tolerated with the dogs experiencing only mild, easily managed side effects such as fever, increased heart rate, and vomiting, consistent with immune activation observed at the time of treatment. The company reports that there is no evidence of any cumulative or long-term side eﬀects on the dogs, which are now being treated on an outpatient basis.
Upon dose selection, the phase 1 study will be advanced to phase 2 and additional collaborative academic centers will be added.
“These early results are significant on several levels,” Dr. Robert Petit, chief scientific officer of Advaxis stated in the press release. “This is the first demonstration of clinical activity with a second Advaxis immunotherapy (in addition to ADXS-HPV) in a naturally developing cancer. These data serve as the foundation for validating Advaxis immunotherapy constructs as a true platform technology, and set the groundwork for future development of a variety of immunotherapies targeting different cancers and infectious diseases. Improving survival in HER2 overexpressing canine osteosarcoma provides direct and important rationale supporting clinical studies in human HER2 overexpressing cancers. As we continue to find the best ways to treat canine osteosarcoma with ADXS-cHER2, the experience we gain will serve to accelerate our development of treatments for similar human cancers.”
ADXS-cHER2 is an Lm-LLO immunotherapy for HER2 overexpressing cancers (such as breast, gastric and other cancers in humans and for osteosarcoma in canines). Advaxis’ goal is to move ADXS-cHER2 into commercial opportunity within the veterinary medical market. The company says it is currently discussing phase 1 data with several veterinary health companies.
ADXS is currently conducting the aforementioned phase 1 study to evaluate the safety and efficacy of ADXS-cHER2 in the treatment of canine osteosarcoma and plan to meet with the U.S. Department of Agriculture, or USDA.
For more information on Advaxis, visit www.advaxis.com
GlobalWise Investments develops and markets enterprise management (ECM) software via wholly owned subsidiary Intellinetics, Inc. The company’s proprietary software delivers cloud-based solutions to better and more cost-effectively manage paper and digital content.
Intellinetics has established a cocktail of management, technology, and business strategy necessary to capture fair market share within the $149 billion business software and services industry, further enhanced by growth in the EMC and cloud-computing markets, which are expected to top $5.7 billion by 2014, and grow by 26 percent between 2010 and 2013, respectively.
Between company CEO William “BJ” Santiago, co-founder and EVP Matthew Chretien, and VP and co-founder A. Michael Chretien, there are more than 66 years of experience in management, technology, sales, consulting, and strategy.
On the technology front, Intellinetics’ Intellivue™ is an advanced document management platform that creates a new industry benchmark in favorable economic and operation impacts. Leading hardware vendors such as Lexmark, Samsung, DELL, and Kodak have selected Intellivue™ cloud platform to improve compliance and disaster recovery, increase service delivery, and reduce costs associated with paper, printing, and filing by up to 77 percent.
Intellinetics also offers a reseller program applicable to hardware manufacturers, value-added reseller and independent software vendors and OEM and ERP partners.
Intellinetics has positioned itself with a high-potential and aggressive stance to capitalize in the rapidly growing and advancing EMC and cloud-computing markets.
For more information, visit www.GlobalWiseInvestments.com
Today's Top 3
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Advaxis, Inc. (ADXSD) Announces ADXS-cHER2 Demonstrates Significant Survival Advantage in Ongoing Canine Osteosarcoma Study
- Cardium Therapeutics, Inc. (CXM) Announces Temporary Adjournment of Annual Meeting To Be Reconvened On July 2, 2013
- DoMark International, Inc. (DOMK) Positioned for Substantial Growth With Imagic's Revolutionary Product for Smartphone & Gaming Enthusiasts Which Has Finalized Development for Production in Q3
- Frozen Food Gift Group Inc. (FROZ) Announces Partnership To Launch Groundbreaking Ice Machine Sanitation Technology
- GlobalWise Investments, Inc. (GWIV) Enters Into New Channel Sales Partnership With TGI Office Automation
- GNCC Capital, Inc. (GNCP) Completes the Acquisition of the White Hills Gold Properties
- GRILLiT®, Inc. (GRLT) Enters LOI to Acquire Third Restaurant Location Near University of Miami Campus
- International Stem Cell Corp. (ISCO) to Present Data From Its Parkinson's Disease Program at Society for Neuroscience Annual Meeting
- Mabwe Minerals Inc. (MBMI) Frames Strategic Alliances With Steinbock Minerals Ltd. and Yasheya Ltd.
- Players Network (PNTV) Launches Las Vegas Lifestyle Channel and Social Community
- Rafarma Pharmaceuticals, Inc. (RAFA) Rafarma Pharmaceuticals Operational Subsidiary Introduces New Board of Directors
- Rainbow Coral Corp. (RBCC) Insurance Companies, Researchers Drive Growth in Personalized Medicine
- Raptor Resources Holdings Inc. (RRHI) Mabwe Minerals Frames Strategic Alliances With Steinbock Minerals Ltd. and Yasheya Ltd.
- Solar Wind Energy Tower, Inc. (SWET) CEO Featured in Exclusive QualityStocks Interview
- StreamTrack, Inc. (STTK) RadioLoyalty Announces the Release of Its New UniversalPlayer™
- The Aristocrat Group Corp. (ASCC) Targets Booming Texas Market for Exclusive Beverage Distribution
- The Guitammer Company Inc. (GTMM) ButtKicker Gamer2, Two "Butts" Are Better Than One
- VentriPoint Diagnostics Ltd. (VPTDF) Announces Closing of Private Placement and Corporate Update
- VistaGen Therapeutics, Inc. (VSTA) Provides Update on $36 Million Strategic Financing Agreement